FMP

FMP

Enter

ARVN - Arvinas, Inc.

Profile of Arvinas, Inc.(ARVN), Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, an

About

ceo

Dr. John G. Houston Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.arvinas.com

exchange

NASDAQ

Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CIK

0001655759

ISIN

US04335A1051

CUSIP

04335A105

Address

5 Science Park

Phone

203 535 1456

Country

US

Employee

445

IPO Date

Sep 27, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep